Labiotech.eu

medical cancer checkpoint inhibitor immunotherapy

News and Trends 29 Apr 2021

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel immune checkpoint target in nearly a decade. This could herald the next generation of checkpoint inhibitors against cancer. Last month, the antibody drug relatlimab, developed by Bristol Myers Squibb, increased the progression-free survival of melanoma patients in phase III. These […]

April 29, 2021 - 5 minutesmins - By Mark Zipkin

Sabine Dandiguian biotech company culture

Expert Advice 28 Apr 2021

How to Build a Successful Company Culture in Biotech

Company culture can be essential to the success of a biotech company. Sabine Dandiguian, Managing Partner at the life sciences VC firm Jeito Capital, shares her experience building a thriving company culture in the life sciences. Company culture is “something very special” that borders on collective intelligence, says Sabine Dandiguian. There are some basics to […]

April 28, 2021 - 8 minutesmins - By Victor Kotsev

multiple sclerosis novartis roche ema approval

News and Trends 27 Apr 2021

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing approaches. Which areas of multiple sclerosis treatment need more options? At the end of March, the EMA made key decisions on three treatments for multiple sclerosis (MS), a chronic neurodegenerative disease affecting 2.5 million people […]

April 27, 2021 - 6 minutesmins - By Jonathan Smith

Opinion 26 Apr 2021

How Good Investor Communications Determine Success in a Covid World

During the pandemic, the biotech industry has continued to complete deals, even without face-to-face interactions. Startups should leverage communication to sustain their investor relations and build strong momentum for late-stage funding rounds in the coming years. Speaking last July, the UK’s Secretary of State for Health and Social Care, Matt Hancock, said the Covid-19 pandemic […]

April 26, 2021 - 6 minutesmins - By External Contributor

Interview 21 Apr 2021

Changing Attitudes on Vaccine and Public Health Investment

The Covid-19 pandemic has pushed investment and research into vaccines and public health, but will such interest continue in the long term? Glenn Rockman, founder and Managing Partner of Adjuvant Capital, a VC firm investing in the infectious disease area, believes it will. Rockman did not plan to get into life science investment. With a […]

April 21, 2021 - 5 minutesmins - By Helen Albert

cardiovascular disease amarin vascepa vazkepa

News and Trends 21 Apr 2021

Vazkepa Gets EMA Nod for Cardiovascular Disease, But Hurdles Remain

Last month’s EU approval of Vazkepa — a treatment derived from fish oil and branded as Vascepa in the US — has added much-needed ammunition to the arsenal of doctors battling cardiovascular disease. Yet other similar treatments are returning lukewarm results and the possibility of approvals being withdrawn hangs in the air. Icosapent ethyl, a […]

April 21, 2021 - 5 minutesmins - By Victor Kotsev

News and Trends 20 Apr 2021

Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions

The US medtech firm Hologic has bought the Finnish-French biotech Mobidiag for around €668M in the latest of a series of mergers, acquisitions, and stock market launches taking over the diagnostics market. Hologic’s move is the latest in a flurry of activity from the women’s health specialist, which has snapped up Diagenode in Belgium, Biotheranostics […]

April 20, 2021 - 5 minutesmins - By Anita Chakraverty

Opinion 19 Apr 2021

The Hidden Costs of Mismanaged R&D Projects in Biotech and Pharma

Mismanagement of R&D projects in biotech and pharma is more common than one might think and can result in high development costs and eventual clinical failure. Can we do something about it? Biotechnology and pharmaceutical businesses are synonymous with both a high risk and an even bigger investment. Bringing new drugs to the market can […]

April 19, 2021 - 7 minutesmins - By Auste Kanapeckaite

neoantigen immuno oncology cancer therapy achilles therapeutics

News and Trends 15 Apr 2021

Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens

The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month may have been a long-delayed starter pistol for investments into neoantigen-based therapies, a family of personalized cancer immunotherapies that target proteins unique to an individual’s tumor. Neoantigen-focused companies have closed smaller initial public offerings (IPOs) in the past. Two major […]

April 15, 2021 - 5 minutesmins - By Mark Zipkin

peanut allergy treatment DBV Technologies Aimmune Viaskin Palforzia

News and Trends 14 Apr 2021

DBV Battles Aimmune for Share of Peanut Allergy Treatment Market

Last year, the FDA rejected DBV Technologies’ peanut allergy treatment and approved that of its rival Aimmune. After recent talks with the FDA and EMA, DBV has laid out a comeback plan that could carve it a niche in the peanut allergy treatment market. The French biotech firm DBV is coming back from a snub by […]

April 14, 2021 - 5 minutesmins - By External Contributor

Interview 5 Apr 2021

Base Editing: The Next Frontier in Genome Editing Technology

Jonathan Frampton, Corporate Development Partner at Horizon Discovery, a Perkin Elmer company, shares his insights into the promises of base editing technology. In less than a decade, the advent of CRISPR-Cas9 has made gene editing easier and faster than ever. But CRISPR, as well as earlier genome editing tools, have a series of technical limitations, […]

April 5, 2021 - 4 minutesmins - By Larissa Warneck-Silvestrin

News and Trends 1 Apr 2021

Have European Investors Missed the Exosome ‘Gold Rush’?

When Oxford-based Evox Therapeutics announced its €81.1M (£69.2M) Series C round in February, it signaled that investors are taking exosome therapies seriously. But a lack of European investors in the exosome field raises the very real possibility that the best opportunities have already passed, along with the chance to build an exosome ecosystem to rival […]

April 1, 2021 - 5 minutesmins - By Mark Zipkin

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

How to Build a Successful Company Culture in Biotech

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

How Good Investor Communications Determine Success in a Covid World

Changing Attitudes on Vaccine and Public Health Investment

Vazkepa Gets EMA Nod for Cardiovascular Disease, But Hurdles Remain

Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions

The Hidden Costs of Mismanaged R&D Projects in Biotech and Pharma

Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens

DBV Battles Aimmune for Share of Peanut Allergy Treatment Market

Base Editing: The Next Frontier in Genome Editing Technology

Have European Investors Missed the Exosome ‘Gold Rush’?

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!